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Modern radiant heat whole body hyperthermia (WBH) safely
permits core body temperatures up to 41.8°C in both animals
and man (Robins et al., 1984; Robins et al., 1985). Tempera-
ture in this range potently sensitise neoplastic cells to cis-
platin cytotoxicity in vitro and in vivo (Meyn et al., 1980;
Barlogie et al., 1980). However, cisplatin nephrotoxicity is
increased to a similar extent (Wondergem et al., 1988; Gerad
et al., 1983) so that WBH offers no therapeutic gain for
cisplatin.
Temperatures compatible with WBH also markedly sen-
sitise various neoplastic cells to carboplatin cytotoxicity in
vitro producing 3 to 5-fold thermal dose modifying factors
(Cohen & Robin, 1987; Cohen et al., 1989a; Cohen et al.,
1990a). The degree of thermal sensitisation for carboplatin is
equivalent to that for cisplatin (Cohen et al., 1989b). Carbo-
platin is also much less neurotoxic and emetogenic than
cisplatin (Calvert et al., 1982; Koeller et al., 1986) an impor-
tant consideration when using a WBH device which does not
require endotracheal intubation or general anaesthesia
(Robins et al., 1985). Most importantly, carboplatin produces
little or no nephrotoxicity (Calvert et al., 1982; Koeller et al.,
1986) even at doses used in autologous bone marrow trans-
plantation (Nichols et al., 1988). Thus, carboplatin appears
to be an ideal agent among the platinum analogues for use
with WBH (Cohen & Robin, 1987).
A key consideration, which has not been addressed pre-
viously, is how WBH affects carboplatin's therapeutic index,
i.e., the drug's relative toxicity for neoplastic vs normal cells.
(Beginning with a report in this journal in 1982, only a few
studies have ever addressed how WBH affects the therapeutic
index of traditional chemotherapeutic agents (Honess &
Bleehen, 1982, Honess & Bleehen, 1985a, Honess &
Bleenhen, 1985b); none of these studies has involved radiant
heat WBH.) Carboplatin's dose limiting toxicity is myelosup-
pression (Calvert et al., 1982; Koeller et al., 1986). Therefore,
in the present studies, we determined the effect of WBH and
carboplatin, separately or in combination, on peripheral
blood leukocyte and platelet counts as well as on the survival
of leukaemic and normal bone marrow stem cells treated in
vivo as measured by spleen colony formation.
For the present studies, WBH was performed as we have
previously described in detail (Robins et al., 1984; Steeves et
al., 1987). In brief, groups of up to 12 6-8 week old, 20 g
female AKR mice were heated simultaneously in a radiant
heat device (Enthermics Medical Systems, Menomonee Falls,
WI). The mice were not anesthetised or restrained. The mice
were ear punched and colour coded on their backs to permit
rapid identification of individual animals for rectal temper-
ature measurements during WBH. These measurements were
conducted for each animal every 10 min without removing
the animals from the WBH chamber. Temperatures (rectal,
ambient air, and heating surface) were recorded using a
model TH-6 basic temperature monitor. Each mouse received
0.5 ml of intraperitoneal normal saline at the initiation of a
heating session. The time to reach target temperature
(41.5 ± 0.5°C) was approximately 60min. Mice were main-
tained at the target temperature for 60 min. Carboplatin
(Investigational Drug Branch, National Cancer Institute -
USA) was given at target temperature as a single intraperi-
toneal injection of 0 mg kg-' (sham injection) or 80 mg kg-'
(1.6 mg in a 20 g mouse) in 1 ml of 5% dextrose solution.
The maximum tolerated carboplatin dose in these mice is
100 mg kg-' at normal body temperature.
White blood cell and platelet counts were determined for
individual animals from 20ll tail vein blood samples using
the Unopette microcollection/dilution system (Becton-Dickin-
son, Rutherford, NJ) and hand-held hemacytometers precise-
ly as we have recently described (Cohen & Robins, 1990b).
Baseline leukocyte and platelet counts were determined pre-
treatment. Thereafter, each treatment group was divided into
smaller groups of three mice. Leukocyte and platelet counts
were performed every 3 to 4 days on groups of three mice in
such a manner that each mouse was bled only every 6 or 7
days. Each blood count was performed in duplicate.
Spleen colony formation was determined as we have pre-
viously described in detail (Flentje et al., 1984; Steeves et al.,
1987): Normal and leukaemia bearing mice (tail vein injec-
tion of 1 x 105 AKR leukaemia cells on day 1) were treated
on day 4. On day 5, femoral and tibial bone marrow plugs
were harvested from normal mice and spleens were harvested
from leukaemia bearing animals. The cell samples were
washed, resuspended and the number of nucleated cells was
determined (Flentje et al., 1984; Steeves et al., 1987). Normal
and leukaemic spleen colon forming units were assayed by
tail vein injection of nucleated normal marrow cells into
lethally irradiated (7.5 Gray, single fraction) and non-
radiated mice respectively. Spleens were removed 8 or 9 days
later, fixed in Bouin's solution and then surface colonies were
visually counted. Spleen colony formation was determined as
the survival fraction ('SF') relative to the spleen colony for-
mation of untreated controls cells, i.e., colony forming
efficiency for cells from untreated control animals was nor-
malised to one (see Steeves et al., 1987). The colony forming
efficiency of normal marrow stem cells was approximately
1.5 10- nucleated cells and 100 to 150 10-4 nucleated cells
for splenic leukaemic cells.
Figure 1 shows the effect of WBH and carboplatin, given
separately or in combination, on the survival of NCFU and
LCFU. WBH alone decreases normal and leukaemic colony
formation (LCFU SF = 0.47 ± 0.07 s.e.m. vs NCFU SF =
0.78 ± 0.09) as does carboplatin alone (LCFU SF = 0.097 +
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Figure 1 Spleen colony forming efficiency of normal marrow
stem cells and AKR leukaemia cells after tail vein injection into
lethally irradiated and non-irradiated female AKR mice respec-
tively. Cells for injection were obtained 24 h post-treatment. The
treatment groups (12 animals in each) received sham intraperi-
toneal carboplatin injections without WBH ('control'), intraperi-
toneal carboplatin without WBH ('CBDCA'), sham carboplatin
injection plus WBH ('WBH'), or carboplatin plus WBH
('WBH + CBDCA'). The colony formation frequency was nor-
malised to one for untreated control animals. Brackets indicate
the standard error of the mean.
0.026, NCFU SF = 0.25 ± 0.10). In combination, WBH and
carboplatin cause substantially lower survival than would be
expected if WBH and carboplatin had simply additive cyto-
toxic interactions (LCFU SF = 0.00055 ± 0.00027 s.e.m.,
NCFU SF = 0.071 ± 0.033). After correcting for direct ther-
mal toxicity, WBH + carboplatin decreased SF 82.9 ± 46.1
(s.e.m.) fold compared to carboplatin alone for LCFU and
2.80 ± 1.74 fold for NCFU (P= 0.0054 for LCFU vs NCFU.
All P values are two sided. Standard errors for the ratios
were calculated using the propagation of errors techniques).
In this same experiment, spleen weights of leukaemia bearing
animals (± standard deviation) were 0.1672 ± 0.028 g (con-
trol), 0.1431 ± 0.013 g (WBH alone), 0.0860 ± 0.013 g (carbo-
platin alone), and 0.0625 ± 0.011 g (WBH plus carboplatin).
Table I summarises pooled data from five murine experi-
ments illustrating the myelosuppressive effects of WBH and
carboplatin given separately or in combination. Compared to
control animals, leukocyte nadirs were lower for mice given
only carboplatin or only WBH (P<0.001 using Student's
t-test). Animals given both carboplatin and WBH had signi-
ficantly lower leukocyte nadirs than did mice given carbo-
platin only or WBH only (P>0.001 for both comparisons).
Similarly, compared to control animals, platelet count nadirs
were decreased for mice given only carboplatin or only WBH
(P<0.0001). Animals given carboplatin plus WBH had
lower platelet nadirs than did mice receiving only carboplatin
or only WBH (P<0.0001).
Figure 2 presents data from a single representative experi-
ment which illustrates the myelosuppressive effects of carbo-
platin with and without WBH. These results are in quanti-
TableI Peripheral bloodleukocyte (day4post-treatment) andplatelet
(day 8 post-treatment) nadirs aftercarboplatin or WBH (41.5°C x 1 h)
in 20 gram AKR mice (±standard error)
Leukocytes mm-3
Carboplatin dose
Temperature 0 mg kg-' 80 mgkg-'
Platelets x 103 mm-3
Carboplatin dose
0 mg kg-' 80 mgkg-'
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Figure 2 Platelet and leukocyte counts in female AKR mice as a
function of time after treatment (time 0) for control *, 41.5°C
whole body hyperthermia (WBH) alone 0, 80mg carboplatin
kg- alone 0, or WBH plus 80 mg carboplatin kg- 0. Brackets
indicate the standard error of the mean.
tative agreement with Table I. This figure illustrates that
WBH does not affect the time course of recovery from
carboplatin-induced thrombocytopenia. Compared to carbo-
platin's effect on peripheral platelet counts, carboplatin-
induced leukocyte count depression was minimal, and was
slightly enhanced by WBH.
In considering the above date, several points are worthy of
discussion. WBH alone and carboplatin alone decrease the
survival of leukaemic cells and normal marrow stem cells
(Figure 1). This effect of WBH alone has been noted pre-
viously in AKR mice (Steeves et al., 1987). WBH alone and
carboplatin alone produce similar degrees of cytotoxicity in
leukaemic and normal cells (with the absolute SF for leu-
kaemic cells being lower; P <0.0004). For WBH plus carbo-
platin the degree of chemosensitisation is greater for
leukaemic cells than for normal cells (P = 0.0054). The reli-
ability of this result is increase by the fact that it was
obtained in vivo using a syngeneic model in which closely
analogous neoplastic and normal cells received the same
WBH-carboplatin regimen. The degree to which 41.5°C
hyperthermia increased carboplatin toxicity for the AKR T
cell leukaemia cells (Figure 1) is consistent with earlier carbo-
platin studies using the JM cell line (a human T cell acute
leukaemia) in vitro at 41.8°C (Cohen & Robins, 1987). The
preferential sensitisation of the AKR leukaemia cells may
relate to the 12 h doubling time of these cells (Steeves et al.,
1987) in contrast to the more heterogeneous behaviour of the
normal marrow stem cells of AKR mice (Robins et al.,
1988).
The peripheral blood counts in Table I provide a second
measure of normal tissue toxicity which correlates closely
with the NCFU results in Figure 1. WBH alone (Table I)
caused small but statistically significant decreases in nadir
counts (only 16% for leukocyte nadirs and 24% for platelet
nadirs); carboplatin alone caused a greater drop in leukocyte
and platelet nadirs (21% and 65% decrease vs control respec-
tively) than did WBH alone (P<0.001); carboplatin plus
WBH caused the greatest reduction (P<0.0001) in leukocyte
and platelet nadirs of any treatment group, i.e., 33% and
78%. Figure 2 graphically illustrates the same effects and
that WBH does not increase the time to platelet count
recovery.
The small effect of WBH alone on blood counts is very
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similar to results in another recent study of WBH in AKR
mice (Robins et al., 1990). In contrast, radiant heat WBH by
itself causes no blood count depression in man (Robins et al.,
1985). WBH does appear to affect carboplatin myelosuppres-
sion in AKR mice (Table I) but not in dogs (Page et al.,
1989) or man (Robins et al., 1991) in an ongoing phase I
study). These differences in toxicity may relate to methodo-
logical differences in performing WBH in these various
species. For example, in man, due to increased metabolic
rate, no appreciable supplemental heat is necessary to main-
tain the target temperature, a time at which bone marrow
undergoes a unique and potentially protective (Robins et al.,
1990) 0.6°C temperature decrease in large mammals (Hugan-
der et al., 1987). This is not the case for rodents (Robins et
al., 1984). There also are pharmacologic differences, e.g.,
intravenous lidocaine and thiopental as well as supplemen-
tary oxygen are given in man (Robins et al., 1985) but not in
the mouse (Robins et al., 1984).
These new data support the view that WBH enhances
carboplatin cytotoxicity more for AKR leukaemia cells than
for normal marrow stem cells (Figure 1), and that WBH has
relatively little effect on carboplatin-induced platelet and
leukocyte count depression. These findings support the con-
cept that WBH might increase carboplatin's therapeutic
index, i.e., increase neoplastic cell killing relative to normal
cell killing. Preliminary clinical observations that WBH does
not alter carboplatin myelosuppression or pharmacokinetics
in man, coupled with observed clinical activity (Robins et al.,
1991), are consistent with this concept.
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